Fate Therapeutics: Q4 Earnings Snapshot

Associated Press Finance03-05

SAN DIEGO (AP) — SAN DIEGO (AP) — Fate Therapeutics Inc. (FATE) on Wednesday reported a loss of $52.2 million in its fourth quarter.

On a per-share basis, the San Diego-based company said it had a loss of 44 cents. Losses, adjusted for asset impairment costs, came to 31 cents per share.

The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 44 cents per share.

The clinical-stage biotech company that develops stem cell treatments posted revenue of $1.9 million in the period, also surpassing Street forecasts. Four analysts surveyed by Zacks expected $1.3 million.

For the year, the company reported a loss of $186.3 million, or $1.64 per share. Revenue was reported as $13.6 million.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2517858924?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-06 05:12","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2517858924","market":"us","top_or_hot":-1,"title":"Fate Therapeutics: Q4 Earnings Snapshot","media":"Associated Press Finance","content":"<html><body><p>SAN DIEGO (AP) — SAN DIEGO (AP) — <a href=\"https://laohu8.com/S/FATE\">Fate Therapeutics Inc</a>. (FATE) on Wednesday reported a loss of $52.2 million in its fourth quarter.</p>\n<p>On a per-share basis, the San Diego-based company said it had a loss of 44 cents. Losses, adjusted for asset impairment costs, came to 31 cents per share.</p>\n<p>The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 44 cents per share.</p>\n<p>The clinical-stage biotech company that develops stem cell treatments posted revenue of $1.9 million in the period, also surpassing Street forecasts. Four analysts surveyed by Zacks expected $1.3 million.</p>\n<p>For the year, the company reported a loss of $186.3 million, or $1.64 per share. Revenue was reported as $13.6 million.</p>\n<p>_____</p>\n<p>This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE</p></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fate Therapeutics: Q4 Earnings Snapshot</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFate Therapeutics: Q4 Earnings Snapshot\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-06 05:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/fate-therapeutics-q4-earnings-snapshot-211223519.html><strong>Associated Press Finance</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>SAN DIEGO (AP) — SAN DIEGO (AP) — Fate Therapeutics Inc. (FATE) on Wednesday reported a loss of $52.2 million in its fourth quarter.\nOn a per-share basis, the San Diego-based company said it had a ...</p>\n\n<a href=\"https://finance.yahoo.com/news/fate-therapeutics-q4-earnings-snapshot-211223519.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FATE","symbol_name":"Fate Therapeutics Inc","start_time":0,"source_url":"https://finance.yahoo.com/news/fate-therapeutics-q4-earnings-snapshot-211223519.html","article_id":"2517858924","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517858924","pubTimestamp":1741209143,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"SAN DIEGO  — SAN DIEGO  — Fate Therapeutics Inc.  on Wednesday reported a loss of $52.2 million in its fourth quarter.On a per-share basis, the San Diego-based company said it had a loss of 44 cents. Losses, adjusted for asset impairment costs, came to 31 cents per share.The results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 44 cents per share.The clinical-stage biotech company that develops stem cell treatments posted revenue of $1.9 million in the period, also surpassing Street forecasts. Four analysts surveyed by Zacks expected $1.3 million.For the year, the company reported a loss of $186.3 million, or $1.64 per share. Revenue was reported as $13.6 million.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"FATE":"Fate Therapeutics Inc"},"translate_title":"Fate Therapeutics：第四季度收益快照","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FATE":1},"content_text":"SAN DIEGO (AP) — SAN DIEGO (AP) — Fate Therapeutics Inc. (FATE) on Wednesday reported a loss of $52.2 million in its fourth quarter.\nOn a per-share basis, the San Diego-based company said it had a loss of 44 cents. Losses, adjusted for asset impairment costs, came to 31 cents per share.\nThe results topped Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 44 cents per share.\nThe clinical-stage biotech company that develops stem cell treatments posted revenue of $1.9 million in the period, also surpassing Street forecasts. Four analysts surveyed by Zacks expected $1.3 million.\nFor the year, the company reported a loss of $186.3 million, or $1.64 per share. Revenue was reported as $13.6 million.\n_____\nThis story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on FATE at https://www.zacks.com/ap/FATE","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517858924"}